ERBB2 and breast carcinoma: In the PALLAS trial, Mayer et al. investigated whether the combination of palbociclib and hormones as a postoperative adjuvant therapy could improve IDFS in hormone-positive, HER2-negative, Stage II and III breast cancer patients (16), (19).